Guillermina Lozano | Academic Influence

Guillermina Lozano's AcademicInfluence.com Rankings

Guillermina Lozano

Biology

#5203

World Rank

#7632

Historical Rank

#1840

USA Rank

Genetics

#663

World Rank

#748

Historical Rank

#230

USA Rank

biology Degrees

Download Badge

Biology

Guillermina Lozano's Degrees

Bachelors Biology University of Texas at Austin

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Guillermina Lozano Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Guillermina 'Gigi' Lozano is an American geneticist. She is a professor at University of Texas MD Anderson Cancer Center. Lozano is recognised for her studies of the p53 tumour suppressor pathway, characterising the protein as a regulator of gene expression .

(See a Problem?)

Guillermina Lozano's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 (1995) (1488)
A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans (2004) (1328)
Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome (2004) (1010)
Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation (2003) (762)
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. (1990) (616)
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 (2001) (528)
MDM2, an introduction. (2003) (446)
p53-independent functions of the p19(ARF) tumor suppressor. (2000) (402)
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2 (1999) (388)
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. (2013) (381)
NF-kappa B activation of p53. A potential mechanism for suppressing cell growth in response to stress. (1994) (373)
Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 (2006) (355)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. (2008) (354)
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice (2004) (327)
A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. (2001) (312)
Mdm2-mediated ubiquitylation: p53 and beyond (2010) (309)
p53 mutation heterogeneity in cancer. (2005) (288)
Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. (2005) (278)
p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. (2012) (271)
Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53* (2002) (267)
Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. (1997) (262)
A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. (2011) (257)
Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment (2015) (254)
Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. (2003) (230)
Synthetic small inhibiting RNAs: Efficient tools to inactivate oncogenic mutations and restore p53 pathways (2002) (225)
Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53‐dependent cellular senescence (2007) (212)
High metastatic potential in mice inheriting a targeted p53 missense mutation. (2000) (206)
14-3-3σ Positively Regulates p53 and Suppresses Tumor Growth (2003) (194)
Functional activation of p53 via phosphorylation following DNA damage by UV but not γ radiation (1998) (193)
USP15 stabilizes MDM2 to mediate cancer cell survival and inhibit antitumor T cell responses (2014) (185)
20 years studying p53 functions in genetically engineered mice (2009) (185)
p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner (2008) (164)
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. (2006) (163)
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy (2012) (160)
Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4 (2006) (157)
14-3-3 sigma positively regulates p53 and suppresses tumor growth. (2003) (157)
An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. (2007) (156)
The loss of mdm2 induces p53 mediated apoptosis (2000) (154)
An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 (2001) (153)
Limiting the power of p53 through the ubiquitin proteasome pathway (2014) (145)
The cenpB gene is not essential in mice (1998) (145)
Novel MYBL1 Gene Rearrangements with Recurrent MYBL1–NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations (2015) (144)
Loss of Gcn5 Acetyltransferase Activity Leads to Neural Tube Closure Defects and Exencephaly in Mouse Embryos (2007) (138)
Cancer: p53 sends nucleotides to repair DNA (2000) (136)
RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. (2003) (134)
Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389 (2004) (134)
Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. (2010) (132)
Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development (2007) (129)
The E3 ubiquitin ligase GRAIL regulates T cell tolerance and regulatory T cell function by mediating T cell receptor-CD3 degradation. (2010) (126)
SV40 T antigen abrogates p53-mediated transcriptional activity. (1993) (125)
Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. (2011) (124)
A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. (2010) (123)
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability (2011) (122)
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. (2011) (121)
The tumor suppressor p53 regulates its own transcription (1993) (119)
Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk (2003) (115)
p21 delays tumor onset by preservation of chromosomal stability (2006) (114)
Multiple stress signals activate mutant p53 in vivo. (2011) (113)
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End. (2016) (111)
Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. (2006) (111)
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. (2012) (109)
Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. (2009) (108)
Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. (1998) (108)
Mutation of Phosphoserine 389 Affects p53 Function in Vivo* (1996) (107)
Analysis of p53 mutants for transcriptional activity (1991) (104)
Mouse models of p53 functions. (2010) (102)
Mutant p53 partners in crime. (2018) (98)
EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model. (2008) (95)
Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. (2011) (95)
Inhibition of endothelial p53 improves metabolic abnormalities related to dietary obesity. (2013) (94)
Regulation of the p53-MDM2 pathway by 14-3-3 σ and other proteins (2006) (94)
Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities (2008) (92)
Mutant p53 partners in crime (2017) (92)
Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation (2000) (91)
p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. (2010) (91)
Bcl-2 inhibits p53 nuclear import following DNA damage (1997) (90)
The oncogenic roles of p53 mutants in mouse models. (2007) (90)
Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells. (2018) (89)
Relationship between simian virus 40 large tumor antigen expression and tumor formation in transgenic mice (1987) (87)
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer (2015) (87)
Mesenchymal Stem Cells and the Origin of Ewing's Sarcoma (2010) (84)
Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets. (2003) (83)
What have animal models taught us about the p53 pathway? (2005) (83)
High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas. (2007) (82)
Tissue‐specific expression of p53 in transgenic mice is regulated by intron sequences (1991) (81)
MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. (2016) (80)
E2F3 Is a Mediator of DNA Damage-Induced Apoptosis (2009) (80)
The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. (1999) (80)
Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma (2009) (78)
Spontaneous tumorigenesis in mice overexpressing the p53-negative regulator Mdm4. (2010) (76)
The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity (2013) (75)
Distinct roles of Mdm2 and Mdm4 in red cell production. (2007) (75)
The Mdm Network and Its Regulation of p53 Activities: A Rheostat of Cancer Risk (2014) (74)
Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. (1998) (73)
Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy (2007) (73)
Crippling p53 activities via knock-in mutations in mouse models (2007) (72)
Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. (2005) (71)
Pla2g16 phospholipase mediates gain-of-function activities of mutant p53 (2014) (71)
Li-Fraumeni Syndrome: a p53 Family Affair (2005) (70)
The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival (2008) (68)
p21 stability: linking chaperones to a cell cycle checkpoint. (2005) (67)
Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair (2010) (67)
p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis (2010) (67)
p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation (2010) (64)
The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo (1997) (64)
Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo (2011) (60)
Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest. (1997) (60)
Gankyrin: an intriguing name for a novel regulator of p53 and RB. (2005) (60)
Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. (2006) (60)
The p53–Mdm2 network in progenitor cell expansion during mouse postnatal development (2007) (54)
The Many Faces of MDM2 Binding Partners. (2012) (54)
Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice (1999) (52)
TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice. (2015) (52)
Conditional allele of mdm2 which encodes a p53 inhibitor (2002) (52)
The mutant p53 mouse as a pre-clinical model (2013) (50)
ASPP2 suppresses squamous cell carcinoma via RelA/p65–mediated repression of p63 (2013) (48)
The organization and expression of the mdm2 gene. (1996) (48)
mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. (1996) (47)
Mdm-2 binding and TAFII31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21 (2002) (46)
An intron binding protein is required for transformation ability of p53. (1991) (46)
Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network (2019) (44)
Disrupting TP53 in mouse models of human cancers (2003) (44)
p53 and MDM2: antagonists or partners in crime? (2009) (43)
Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations (2010) (43)
p53 and Fas ligand are required for psoralen and UVA-induced apoptosis in mouse epidermal cells (2002) (43)
CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo (2018) (42)
Tissue‐specific and age‐dependent effects of global Mdm2 loss (2014) (42)
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target (2007) (42)
MDM2 function. (1998) (41)
The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence. (2017) (41)
Mammary tumor modifiers in BALB/cJ mice heterozygous for p53 (2007) (40)
Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family (1998) (38)
Mouse models dissect the role of p53 in cancer and development. (1998) (38)
DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. (2013) (38)
Adenoviral E1A Targets Mdm4 to Stabilize Tumor Suppressor p53 (2004) (38)
Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation (2012) (37)
Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. (2003) (37)
p53 tetramerization: at the center of the dominant-negative effect of mutant p53 (2020) (36)
Differential roles of p21(Waf1) and p27(Kip1) in modulating chemosensitivity and their possible application in drug discovery studies. (2001) (36)
Grail as a molecular determinant for the functions of the tumor suppressor p53 in tumorigenesis (2013) (35)
Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein (2017) (34)
AACR Cancer Progress Report 2012 (2012) (33)
MDM4/HIPK2/p53 cytoplasmic assembly uncovers coordinated repression of molecules with anti-apoptotic activity during early DNA damage response (2015) (32)
Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. (2009) (31)
Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. (2021) (30)
MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. (2005) (30)
Mtbp haploinsufficiency in mice increases tumor metastasis (2008) (30)
Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases (2018) (30)
Cyclin E restores p53 activity in contact-inhibited cells (1995) (30)
A deficiency in Mdm2 binding protein (MTBP) inhibits Myc-induced B cell proliferation and lymphomagenesis (2010) (29)
Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop (2011) (29)
Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models (2011) (29)
Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. (1999) (29)
An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients (2008) (28)
Dissecting the p53-Mdm2 feedback loop in vivo: uncoupling the role in p53 stability and activity (2014) (27)
Therapeutic Efficacy of p53 Restoration in Mdm2-Overexpressing Tumors (2014) (27)
The ups and downs of p53 regulation in hematopoietic stem cells (2011) (26)
Mutant p53 in concert with an interleukin‐27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice (2016) (26)
Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li–Fraumeni syndrome (2011) (26)
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis (2017) (25)
Germ Cell Expression of an Isolated Human Endogenous Retroviral Long Terminal Repeat of the HERV-K/HTDV Family in Transgenic Mice (1999) (25)
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner (2013) (25)
Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer (2014) (23)
Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma (2017) (22)
Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment (2015) (22)
Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. (2011) (22)
Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice (2015) (21)
Serotonin 5-HT1C receptors are expressed at high density on choroid plexus tumors from transgenic mice (1986) (21)
Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation (2015) (19)
Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis resulting in B-cell lymphoma (2015) (19)
p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo (2020) (18)
Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality (1997) (18)
Distinct downstream targets manifest p53-dependent pathologies in mice (2016) (18)
Characterization of a murine p53SER246 mutant equivalent to the human p53SER249 associated with hepatocellular carcinoma and aflatoxin exposure (1995) (18)
The p53 family grows old. (2012) (18)
p53-independent functions of the p19 tumor suppressor (2000) (17)
Restoring p53 in cancer: the promises and the challenges (2019) (17)
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice (2004) (17)
Mdm proteins: critical regulators of embryogenesis and homoeostasis (2017) (16)
Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo (2016) (15)
EWS-FLI 1 Induces Developmental Abnormalities and Accelerates Sarcoma Formation in a Transgenic Mouse Model (2008) (15)
Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. (2004) (15)
Heterozygous p53V172F mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53 (2016) (14)
Daxx maintains endogenous retroviral silencing and restricts cellular plasticity in vivo (2020) (14)
Limiting the power of p 53 through the ubiquitin proteasome pathway (2014) (14)
p53: Multiple Facets of a Rubik's Cube. (2017) (13)
Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland (2002) (13)
A novel genetic modifier of p53, mop1, results in embryonic lethality (2004) (12)
Mutant p53 Disrupts Role of ShcA Protein in Balancing Smad Protein-dependent and -independent Signaling Activity of Transforming Growth Factor-β (TGF-β)* (2011) (12)
Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells. (1996) (12)
Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes (2018) (12)
MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. (2021) (11)
Men1 maintains exocrine pancreas homeostasis in response to inflammation and oncogenic stress (2020) (11)
Transient enhancement of p53 activity protects from radiation-induced gastrointestinal toxicity (2019) (11)
TP53 mutation and haplotype analysis of two large African American families (1999) (10)
Model Predictions of MDM2 Mediated Cell Regulation (2004) (10)
Genome-wide association tests of inversions with application to psoriasis (2014) (10)
Comparison of sample-labeling techniques in DNA microarray experiments (2004) (10)
Structural and functional analysis of p53: the acidic activation domain has transforming capability. (1994) (9)
Mouse Models of p 53 Functions (2009) (9)
Constitutive Dicer1 phosphorylation accelerates metabolism and aging in vivo (2018) (9)
Mdm 2 and Mdm 4 Loss Regulates Distinct p 53 Activities (2008) (9)
New mouse models of cancer: Single-cell knockouts (2007) (9)
Daxx Functions Are p53-Independent In Vivo (2018) (9)
Mdm proteins: critical regulators of embryogenesis and homoeostasis. (2017) (9)
A functionally inactive p53 Li-Fraumeni syndrome mutant. (1993) (8)
A spontaneous model of spondyloarthropathies that develops bone loss and pathological bone formation: A process regulated by IL27RA-/- and mutant-p53 (2018) (8)
The Enigma of p53. (2016) (7)
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancer (2021) (7)
Wnt/ß-catenin-mediated p53 suppression is indispensable for osteogenesis of mesenchymal progenitor cells (2021) (6)
Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination. (2019) (6)
Novel p53 germline mutation in a patient with Li−Fraumeni syndrome (2003) (6)
Tumorigenesis promotes Mdm4-S overexpression (2017) (6)
Sox2+ cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence (2019) (6)
The expression of viral and cellular genes in papillomas of the choroid plexus induced in transgenic mice. (1988) (6)
p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis (2015) (6)
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration (2018) (5)
Critical role for Ser 20 of human p 53 in the negative regulation of p 53 by Mdm 2 (2013) (5)
Loss of digestive organ expansion factor (Diexf) reveals an essential role during murine embryonic development that is independent of p53 (2017) (5)
Developmental control of transcription of the cat reporter gene by a truncated mouse alphafetoprotein gene regulatory region in transgenic mice (1995) (5)
A blood-based polyamine signature associated with MEN1 duodenopancreatic neuroendocrine tumor progression. (2021) (5)
Mouse modeling provides insights into Daxx and Atrx tumor suppressive mechanisms in the endocrine pancreas. (2022) (4)
Differential gain-of-function activity of three p53 hotspot mutants in vivo. (2022) (4)
TNBC invasion: downstream of STAT3 (2017) (4)
Che‐ating death: CHE1/AATF protects from p53‐mediated apoptosis (2012) (3)
SNPing away at mutant p53 activities (2018) (3)
Omics analyses of a somatic Trp53R245W/+ breast cancer model identify cooperating driver events activating PI3K/AKT/mTOR signaling (2022) (3)
p53 Activation Paradoxically Causes Liver Cancer. (2022) (3)
Molecular and Cellular Pathobiology Multiple Stress Signals Activate Mutant p 53 In Vivo (2011) (3)
Regulation of p53 Activity and Associated Checkpoint Controls (2010) (2)
You can win by losing: p53 mutations in rhabdomyosarcomas (2010) (2)
Building p53. (2010) (2)
Mutant p53-driven tumorigenesis (2013) (2)
A convenient cloning vector containing the GAL4 DNA-binding domain. (1992) (2)
Analysis of Population Differences in Digital Conversations About Cancer Clinical Trials: Advanced Data Mining and Extraction Study (2020) (2)
The Common Germline TP53-R337H Mutation Is Hypomorphic and Confers Incomplete Penetrance and Late Tumor Onset in a Mouse Model (2021) (2)
Transcriptional Regulation by Tumor Suppressor Genes (1995) (1)
BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status (2013) (1)
Molecular Pathways Molecular Pathways : Targeting Mdm 2 and Mdm 4 in Cancer Therapy (2012) (1)
Developing genetically engineered mouse models to study tumor suppression. (2012) (1)
Alterations of the MDM2 C-terminus differentially impact its function in vivo. (2022) (1)
Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss (2022) (1)
Functional characterization of inherited p53 mutations (1994) (1)
Genotype-to-Phenotype Associations in the Aggressive Variant Prostate Cancer Molecular Profile (AVPC-m) Components (2022) (1)
Tissue specificity and spatio-temporal dynamics of the p53 transcriptional program (2023) (1)
Use of a murine model of NSCLC to evaluate the role of the microRNA-200 family in regulating EMT and metastasis. (2009) (1)
Dimeric p53 Mutant Elicits Unique Tumor-Suppressive Activities through an Altered Metabolic Program. (2023) (1)
Abstract 1069: Mutant p53 disrupts the role of ShcA in balancing the Smad-dependent and -independent signaling activity of TGF-β (2012) (0)
Haploinsufﬁciency of Mdm2 and Mdm4 in Tumorigenesis and Development (cid:1) (2007) (0)
Peripheral tolerance and lymphocyte anergy (PP-072) (2010) (0)
Abstract SY07-03: Gain-of-function activities of mutant p53 (2014) (0)
Abstract IA21: Mutant p53 activities in tumor development. (2016) (0)
Signals regulating p53- and Rb-mediated negative cell growth (1995) (0)
Abstract B07: Gain of function activities of p53R245W in a conditional knock-in mouse model (2016) (0)
Abstract 2417: Mutant p53 and oncogenic KRAS converge on CREB1 to drive pancreatic cancer metastasis (2021) (0)
One step at a time (2018) (0)
Abstract SY14-02: p53-mediated senescence impairs the apoptotic response to chemotherapy in breast cancer (2012) (0)
Genome-wide association tests of inversions with application to psoriasis (2014) (0)
Abstract 829: p53 dimers elicit tumor suppressive activities through an altered metabolic program (2022) (0)
Is loss of p53 a driver of ductal carcinoma in situ progression? (2022) (0)
DEAR1, a novel tumor suppressor, negative regulator of epithelial-mesenchymal transition, and prognostic factor in non-small cell lung cancer. (2012) (0)
COP 9 signalosome subunit 6 promotes tumorigenesis through stabilization of MDM 2 (2010) (0)
target for modulating p 53 induction after DNA damage-UTR interactions regulate p 53 mRNA translation and provide a ′ 3 − ′ 5 Material Supplemental (2010) (0)
Abstract IA-3: The regulation of p53 tumor suppressing activities (2009) (0)
Abstract #2342: Tumor suppression and drug response in MMTV Wnt transgenic mice harboring p53 point mutations (2009) (0)
Abstract 3030: Mutant p53-driven metastasis explored utilizing a traceable, conditional osteosarcoma model (2017) (0)
Abstract 1459: Mining for metastasis genes in osteosarcomas fromp53+/R172Hmice (2011) (0)
TheTumorSuppressor p53Regulates ItsOwn Transcription (1993) (0)
Bcl-2 Protects against p53-Induced Apoptosis through Hdm2 (2008) (0)
Fresh tissue harvest and histopathologic processing of uveal melanoma specimens: Implications for basic research and patient care (2005) (0)
Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor (2007) (0)
Context matters – Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas (2022) (0)
p53-Mediated Stress and Tissue-Dependent Cell Fate Decisions; Implications for p53 Targeting (2011) (0)
EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma (2022) (0)
S039 Activation of the Gain-of-Function p53R172H Allele Predisposes to Oral Cancer Progression (2006) (0)
Abstract 1235: Induction of a p21 mediated senescence program by p53 impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer (2011) (0)
Abstract P3-03-03: A mouse model of sporadic breast tumor with a conditionalP53mutation (2016) (0)
Abstract 1958: Signals activating mutant p53 in vivo (2010) (0)
Abstract A19: Phosphorylation results in nuclear translocation of Dicer protein that increases metabolism, accelerates aging, and alters tumorigenesis (2018) (0)
2003 – MDMX ACTS AS A PERVASIVE PRELEUKEMIC-TO-ACUTE MYELOID LEUKEMIA SWITCH MECHANISM (2020) (0)
Oncogenes and Tumor Suppressors Therapeutic Ef fi cacy of p 53 Restoration in Mdm 2-Overexpressing Tumors (2015) (0)
Abstract SY29-02: The Mdm2/Mdm4 complex: A rheostat for p53 activity (2010) (0)
Cancer esearch cular and Cellular Pathobiology ntaneous Tumorigenesis in Mice Overexpressing the R-Negative Regulator Mdm 4 in (2010) (0)
Cancer del ano : tratamiento quirurgico (1986) (0)
A critical role of GRAIL in T cell activation and tolerance (50.18) (2010) (0)
Regulation of naïve T cell tolerance and regulatory T cell function by GRAIL (113.21) (2011) (0)
CBMT-32. EGFR SUPPRESSES p53 FUNCTION THROUGH DNA-PKcs BINDING TO p53: NOVEL CROSSTALK BETWEEN EGFR AND TP53 IN GLIOBLASTOMA (2019) (0)
Oncogenes and Tumor Suppressors p 53 Activity Dominates That of p 73 upon Mdm 4 Loss in Development and Tumorigenesis (2016) (0)
Abstract SY04-01: The in vivo gain-of-function activities of mutant p53 (2016) (0)
Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases (2018) (0)
Inhibition of the mutant p53 gene in transformation assays. (1992) (0)
Abstract 3917: Understanding the mechanisms driving pancreatic neuroendocrine tumorigenesis (2014) (0)
Structural and Functional Analysis of p53: The Acidic Activation Domain Has (1994) (0)
Abstract A17: p53 missense mutants R172H and R270H exhibit differential effects on tumorigenesis (2015) (0)
Abstract P066: Blood-based proteomic signatures associated with MEN1-related duodenopancreatic neuroendocrine tumor progression (2023) (0)
Abstract A042: Differences in gain-of-function and inhibitory effects amongst p53 mutants in vivo (2023) (0)
Nuclear protein binds intron 4 of the p53 oncogene (1989) (0)
Genetic mapping of a putative tumor suppressor locus that influences tumorigenesis and metastasis in mice (2006) (0)
Abstract IA08: Somatic p53 mutations drive development of triple-negative breast cancer with evolutionarily distinct metastases (2018) (0)
Abstract CN02-01: Factors that impinge on the p53 pathway modify cancer risk (2013) (0)
Overexpression of the p53 inhibitor MDM4 in Head and Neck Squamous Carcinomas (2009) (0)
CRISPR/Cas9 can mediate high-efficiency off-target mutations in mice in vivo (2018) (0)
Metastatic lung cancer induced by the cooperation ofp53 and K-ras mutations in mice (2004) (0)
CBIO-02. AMPLIFIED EGFR DRIVES TUMORIGENESIS IN TP53 WILD TYPE GLIOBLASTOMA THROUGH INHIBITION OF p53 FUNCTION BY DNA-PK/p53 BINDING (2017) (0)

This paper list is powered by the following services:

Other Resources About Guillermina Lozano

en.wikipedia.org

What Schools Are Affiliated With Guillermina Lozano?

Guillermina Lozano is affiliated with the following schools: